VJHemOnc is committed to improving our service to you

ASCO 2020 | Teclistamab: BCMA x CD3 bispecific antibody in RRMM

VJHemOnc is committed to improving our service to you

Saad Usmani

Saad Usmani, MD, FACP, Levine Cancer Institute & Atrium Health, Charlotte, NC, talks through the results from the phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter